TEM Stock Forecast & Price Target

Tempus AI is benefiting from a sharper fundamental story as positive INTerpath-001 results strengthen the strategic logic of its Personalis acquisition and validate individualized neoantigen therapy, potentially expanding biopharma sequencing demand and improving the quality of the asset it is acquiring. The company also gained a meaningful product catalyst with FDA 510(k) clearance for Tempus ECG-PH, its third FDA-cleared cardiovascular product, which broadens the addressable cardiology market and reinforces the scalability of its ECG-AI platform. Beyond that, FDA approval of tumor-only xT CDx creates a near-term earnings driver through unified ADLT pricing, with management expecting about $85M of annual revenue from xT beginning in 2027 and roughly $400M of incremental revenue in 2028 from xT and xF.

Tempus AI is facing a fundamentally challenging setup because its valuation depends on sustaining strong sales growth, yet the cited risks point to slower-than-expected demand from competition, regulatory uncertainty, and technological obsolescence. The business also faces execution and commercial hurdles, including the need for additional product approvals, customer retention, and sustainable profitability, while potential dilution could pressure shareholders. Reimbursement and integration risks are especially concerning, as no formal CDx designation has been issued for Intismeran, commercial payer contracts are not yet disclosed, and Medicare coverage does not ensure broader commercial adoption.